Who Owns Dishman Carbogen Amcis Company?

Dishman Carbogen Amcis Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Dishman Carbogen Amcis Limited?

Understanding a company's ownership is key to grasping its strategy and accountability. Recent events, like the August-September 2025 postal ballot to boost authorized share capital, show how shareholder decisions directly impact a company's financial future and operational capacity.

Dishman Carbogen Amcis Limited is a global contract development and manufacturing organization serving the pharmaceutical and biopharmaceutical sectors. Founded in 1983 by Shri Janmejay R. Vyas, the company evolved from its initial focus on research and development for quaternary ammonium compounds and active pharmaceutical ingredients.

As of June 2025, Dishman Carbogen Amcis Limited has a market capitalization of approximately ₹4,227.66 crores (around $485 million as of August 21, 2025). It is publicly traded on both the Bombay Stock Exchange and the National Stock Exchange of India. The ownership structure includes substantial promoter holding, institutional investors, and public shareholders, typical for established Indian pharmaceutical firms. This structure influences its corporate trajectory, as seen in its ongoing efforts to raise funds for growth. The company's portfolio includes services for complex molecules, and a look at its Dishman Carbogen Amcis PESTEL Analysis can provide further context on its operating environment.

The foundation of Dishman Carbogen Amcis Limited traces back to the Dishman Group, established in 1983 by Shri Janmejay R. Vyas. His initial focus was on research and development for in-house technologies, particularly in quaternary ammonium compounds and active pharmaceutical ingredients. While early investment details are not public, the company's growth was driven by its founder's vision.

Founder's Vision

Shri Janmejay R. Vyas envisioned a company driven by innovation in chemical compounds and pharmaceutical ingredients.

Early Focus Areas

The initial operations centered on developing proprietary technologies for quaternary ammonium compounds and active pharmaceutical ingredients (APIs).

Corporate Evolution

The entity that became Dishman Carbogen Amcis Limited was formally incorporated on July 17, 2007, as Carbogen Amcis (India) Limited.

Strategic Acquisitions

Key acquisitions, including the Swiss-based CARBOGEN AMCIS AG in 2006, significantly shaped the company's global presence.

Family Involvement

The Vyas family, including Janmejay R. Vyas and others, played a vital role in early ownership transfers and restructuring.

Global Integration

These strategic moves transformed the company into a globally integrated provider of pharmaceutical services.

The formal incorporation of the entity that would become Dishman Carbogen Amcis Limited occurred on July 17, 2007, under the name Carbogen Amcis (India) Limited. This followed significant strategic acquisitions, notably the Swiss-based CARBOGEN AMCIS AG in 2006 and a vitamin and cholesterol business in 2007, which transformed Dishman into a global organization. The Vyas family, including Janmejay R. Vyas, Deohooti J. Vyas, Aditi J. Vyas, Mansi J. Vyas, and Arpit J. Vyas, played a crucial role in early ownership transfers and restructuring, such as the sale of stakes in subsidiaries like Dishman Biotech Ltd. and Dishman Infrastructure Ltd. in 2016-2017. These early transactions solidified the founding family's control and reflected their strategic vision for a globally integrated pharmaceutical services provider. Understanding these early stages is key to grasping the current Dishman Carbogen Amcis ownership structure and the Competitors Landscape of Dishman Carbogen Amcis.

Key Ownership Milestones

The Vyas family has been instrumental in shaping the ownership and strategic direction of the company since its inception.

• Establishment of the Dishman Group in 1983 by Shri Janmejay R. Vyas.
• Incorporation of Carbogen Amcis (India) Limited in 2007.
• Acquisition of CARBOGEN AMCIS AG in 2006.
• Strategic divestments of subsidiary stakes by the Vyas family in 2016-2017.
• Founding family's continued influence on corporate governance and strategic decisions.

Dishman Carbogen Amcis SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Dishman Carbogen Amcis Limited's ownership journey began with its public listing on September 21, 2017, following a significant scheme of arrangement. A subsequent IPO bidding period from January 27, 2020, to July 24, 2020, aimed to bolster its capital base. As of June 2025, the company's market capitalization reached approximately ₹4,227.66 crores.

The promoter group continues to be the dominant force in Dishman Carbogen Amcis Limited's ownership, maintaining a stable stake of 59.32% as of the June 2025 quarter. Within this group, Adimans Technologies Private Limited stands out as the largest single shareholder, holding 59% of the outstanding shares as of April 2025, signifying substantial control. Institutional investors, comprising Foreign Portfolio Investors (FPIs) and Domestic Institutional Investors (DIIs), collectively increased their stake to 11.21% in June 2025 from 10.75% in March 2025. This growth was primarily driven by FPIs, whose holdings rose from 9.49% to 9.94% over the same period, with mutual funds also showing a slight uptick. Key institutional stakeholders include HBM Partners Ltd. (3.57% as of June 29, 2025), Massachusetts Institute of Technology Investment Management Company (2.28% as of June 29, 2025), and Dimensional Fund Advisors LP (0.90% as of July 30, 2025). The general public accounts for a significant 29.5% stake as of June 2025. These ownership dynamics highlight a blend of consistent promoter control and growing institutional interest, reflecting evolving market perceptions and the company's strategic direction, which is further detailed in the Growth Strategy of Dishman Carbogen Amcis.

Key Stakeholder Breakdown

Understanding the ownership structure is crucial for assessing corporate governance and strategic decision-making.

• Promoter group holds the majority stake, ensuring strategic continuity.
• Institutional investors show increasing confidence, particularly FPIs.
• Adimans Technologies Private Limited is the largest single shareholder.
• The general public represents a substantial portion of the ownership.

Dishman Carbogen Amcis PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Dishman Carbogen Amcis Limited is structured to balance family representation with independent oversight. As of May 2025, following the passing of Chairman Shri Janmejay R. Vyas, the board continues its governance with key family members and newly appointed independent directors, aiming to guide the company's strategic direction.

The voting power within Dishman Carbogen Amcis Limited operates on a standard one-share-one-vote system, common for publicly traded entities in India. While specific details on dual-class shares are not publicly indicated, the significant promoter holding, amounting to approximately 59.32% primarily through Adimans Technologies Private Limited, confers substantial control to the founding family and associated entities over critical decision-making processes. This strong promoter influence suggests a governance framework where the founding vision remains a dominant force, with no recent reports of significant shareholder disputes or activist interventions that would alter this dynamic.

Key Aspects of Dishman Carbogen Amcis Governance

The company's board composition reflects a blend of family stewardship and independent expertise. The substantial promoter stake ensures a clear line of strategic direction, while independent directors contribute to robust corporate governance.

• Founding family members hold key directorial positions, ensuring continuity of vision.
• Independent directors provide objective oversight and strategic guidance.
• The voting structure is based on a one-share-one-vote principle.
• Promoter holding, at 59.32%, signifies strong controlling interest.
• The company's governance structure appears stable with significant promoter influence.
• For a deeper understanding of the company's guiding principles, explore the Mission, Vision & Core Values of Dishman Carbogen Amcis.

Dishman Carbogen Amcis Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments at Dishman Carbogen Amcis Limited in 2024 and 2025 have brought about significant shifts in its leadership and strategic financial planning, impacting its ownership trends. The company is actively seeking shareholder approval for a substantial capital raise, which could influence the existing Dishman Carbogen Amcis ownership structure.

The ownership trends for Dishman Carbogen Amcis Limited indicate a growing interest from institutional investors, with Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs) increasing their stake from 9.49% in March 2025 to 9.94% by June 2025. Similarly, Mutual Fund holdings saw a marginal rise from 1.06% to 1.07% in the same period, contributing to a total institutional investor holding of 11.21% in the June 2025 quarter. This suggests a positive sentiment among professional investors regarding the company's strategic direction and growth prospects, especially in specialized areas like Antibody-Drug Conjugate (ADC) manufacturing, as evidenced by a CHF 25 million co-investment agreement in June 2025. The company's focus remains on strengthening its financial foundation and expanding its global presence, while navigating leadership transitions, which are crucial for maintaining stability among Dishman Carbogen Amcis stakeholders.

Leadership Transitions

The company experienced leadership changes with the passing of its Chairman and the stepping down of the CEO of its Carbogen Amcis entities. New appointments aim to ensure continuity and strategic direction.

Capital Infusion Plans

A significant capital raise of up to ₹1,000.00 crore is planned to reduce debt and fund general corporate needs. This move may lead to some dilution in existing shareholding percentages.

Institutional Investor Confidence

There's a noticeable uptick in holdings by FII/FPI and Mutual Funds, indicating increased confidence from institutional investors in the company's future performance and Target Market of Dishman Carbogen Amcis.

Strategic Expansion in ADC Manufacturing

A CHF 25 million co-investment agreement in June 2025 highlights the company's commitment to enhancing its capabilities in the high-value Antibody-Drug Conjugate sector.

Dishman Carbogen Amcis Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔